[go: up one dir, main page]

NO20015845D0 - Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyclo(2.2.2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-amincitrat som NK-1 reseptor antagonister - Google Patents

Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyclo(2.2.2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-amincitrat som NK-1 reseptor antagonister

Info

Publication number
NO20015845D0
NO20015845D0 NO20015845A NO20015845A NO20015845D0 NO 20015845 D0 NO20015845 D0 NO 20015845D0 NO 20015845 A NO20015845 A NO 20015845A NO 20015845 A NO20015845 A NO 20015845A NO 20015845 D0 NO20015845 D0 NO 20015845D0
Authority
NO
Norway
Prior art keywords
benzhydryl
azabicyclo
methoxybenzyl
iso
oct
Prior art date
Application number
NO20015845A
Other languages
English (en)
Other versions
NO20015845L (no
Inventor
Stephen Sargent Massett
George Joseph Quallich
Peter Robert Rose
Lewin Theophilus Wint
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20015845D0 publication Critical patent/NO20015845D0/no
Publication of NO20015845L publication Critical patent/NO20015845L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20015845A 1999-06-01 2001-11-30 Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyklo(2.2.2)okt-3-yl)-(5-isopropyl-2-metoksybenzyl)-amin-citrat som NK-1-reseptorantagonister NO20015845L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13699599P 1999-06-01 1999-06-01
PCT/IB2000/000663 WO2000073303A1 (en) 1999-06-01 2000-05-17 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists

Publications (2)

Publication Number Publication Date
NO20015845D0 true NO20015845D0 (no) 2001-11-30
NO20015845L NO20015845L (no) 2002-01-30

Family

ID=22475353

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015845A NO20015845L (no) 1999-06-01 2001-11-30 Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyklo(2.2.2)okt-3-yl)-(5-isopropyl-2-metoksybenzyl)-amin-citrat som NK-1-reseptorantagonister

Country Status (38)

Country Link
US (1) US6387925B1 (no)
EP (1) EP1181289A1 (no)
JP (1) JP2003501353A (no)
KR (1) KR20020005055A (no)
CN (1) CN1353712A (no)
AP (1) AP2001002350A0 (no)
AR (1) AR029753A1 (no)
AU (1) AU767331B2 (no)
BG (1) BG106139A (no)
BR (1) BR0011125A (no)
CA (1) CA2372236A1 (no)
CO (1) CO5170468A1 (no)
CR (1) CR6513A (no)
CZ (1) CZ20014270A3 (no)
DZ (1) DZ3051A1 (no)
EA (1) EA004206B1 (no)
EE (1) EE200100655A (no)
GT (1) GT200000086A (no)
HK (1) HK1046407A1 (no)
HN (1) HN2000000076A (no)
HR (1) HRP20010884A2 (no)
HU (1) HUP0201798A3 (no)
IL (1) IL145952A0 (no)
IS (1) IS6129A (no)
MX (1) MXPA01012328A (no)
NO (1) NO20015845L (no)
NZ (1) NZ514762A (no)
OA (1) OA11955A (no)
PA (1) PA8496001A1 (no)
PE (1) PE20010155A1 (no)
PL (1) PL352715A1 (no)
SK (1) SK17342001A3 (no)
SV (1) SV2002000092A (no)
TN (1) TNSN00119A1 (no)
TR (1) TR200103472T2 (no)
UY (1) UY26177A1 (no)
WO (1) WO2000073303A1 (no)
ZA (1) ZA200109839B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031191A1 (en) * 2002-10-04 2004-04-15 Merck Sharp & Dohme Limited Azabicyclic spiroether derivatives as receptor antagonists
CA2529820A1 (en) * 2003-06-18 2004-12-29 Teva Pharmaceutical Industries Ltd Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
US7371906B2 (en) 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
JPH0733386B2 (ja) * 1991-05-31 1995-04-12 フアイザー・インコーポレイテツド キヌクリジン誘導体
AU676489B2 (en) * 1992-11-12 1997-03-13 Pfizer Inc. Quinuclidine derivative as substance P antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

Also Published As

Publication number Publication date
EA200100982A1 (ru) 2002-06-27
AU767331B2 (en) 2003-11-06
ZA200109839B (en) 2003-01-29
NO20015845L (no) 2002-01-30
KR20020005055A (ko) 2002-01-16
BG106139A (bg) 2002-05-31
UY26177A1 (es) 2000-12-29
IS6129A (is) 2001-10-26
JP2003501353A (ja) 2003-01-14
HK1046407A1 (zh) 2003-01-10
HN2000000076A (es) 2001-02-02
TNSN00119A1 (fr) 2005-11-10
CA2372236A1 (en) 2000-12-07
WO2000073303A1 (en) 2000-12-07
US6387925B1 (en) 2002-05-14
AR029753A1 (es) 2003-07-16
SV2002000092A (es) 2002-02-05
PA8496001A1 (es) 2002-07-30
EE200100655A (et) 2003-02-17
MXPA01012328A (es) 2002-07-30
BR0011125A (pt) 2002-02-19
HUP0201798A3 (en) 2002-10-28
TR200103472T2 (tr) 2002-05-21
OA11955A (en) 2006-04-13
EP1181289A1 (en) 2002-02-27
CO5170468A1 (es) 2002-06-27
CZ20014270A3 (cs) 2002-08-14
PE20010155A1 (es) 2001-02-08
SK17342001A3 (sk) 2002-10-08
NZ514762A (en) 2002-12-20
HUP0201798A2 (en) 2002-09-28
AU4424600A (en) 2000-12-18
DZ3051A1 (fr) 2004-03-27
CN1353712A (zh) 2002-06-12
IL145952A0 (en) 2002-07-25
EA004206B1 (ru) 2004-02-26
AP2001002350A0 (en) 2001-12-31
CR6513A (es) 2003-11-25
PL352715A1 (en) 2003-09-08
HRP20010884A2 (en) 2003-04-30
GT200000086A (es) 2001-11-21

Similar Documents

Publication Publication Date Title
WO2002012442A3 (en) Heterocyclic compounds as ligands of the gabaa receptor
NO20004606D0 (no) FremgangsmÕte for fremstilling av epoksider fra olefiner
DK1173440T3 (da) Tetracycliske azepinoindolforbindelser som 5-HT receptorligander
IS5539A (is) 4-(2-ketó-1-bensímidazólinýl) píperidín efnasambönd sem mótlyf fyrir orl 1-viðtaka
NO20025186L (no) Fremgangsmåte for syntese av en ecteinascidinforbindelse
PL356034A1 (en) Cyclic amine compounds as ccr5 antagonists
NO965036D0 (no) Kinolinderivater som techykinin NK3 reseptor-antagonister
DK1140828T3 (da) 3-Azabicyclo[3.1.0]hexan-derivater som opiat-receptorligander
NO20004261D0 (no) 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin- reseptor antagonister
DK1440059T3 (da) 3-azabicyclo(3.1.0)hexanderivater som opioidreceptorantagonister
NO20006039D0 (no) Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin
HK1045834A1 (zh) 緩激肽受體拮抗劑
NO20024321D0 (no) Fremgangsmåte for fremstilling av krystallinsk form I av kabergolin
NO20016187L (no) Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister
ID28601A (id) Proses penyiapan senyawa-senyawa 1,4-dihidropiridin
NO20014356L (no) Bifenylderivater som antagonister av neurokinin-1 reseptoren
NO20015845D0 (no) Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyclo(2.2.2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-amincitrat som NK-1 reseptor antagonister
WO2002092602A3 (en) PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-f] QUINOLINE
NO985970L (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
AU3611099A (en) Oxindole derivatives used as neurokinin receptor antagonists
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
NO20035547D0 (no) Fremgangsmåte for fremstilling av paroksetin HCl som begrenser dannelse avrosafargede forbindelser
NO20010629D0 (no) Fremgangsmåte for fremstilling av en ikke-krystallinsk anhydratform av paroksetinhydroklorid
DK1133495T3 (da) Semihydrochlorid af 8-cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-quinolincarboxylsyre
NO943101D0 (no) 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application